PHAXIAM Therapeutics (XPAR:PHXM) Total Receivables : €0.00 Mil (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics Total Receivables?

PHAXIAM Therapeutics's Total Receivables for the quarter that ended in Sep. 2023 was €0.00 Mil.

PHAXIAM Therapeutics Total Receivables Historical Data

The historical data trend for PHAXIAM Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Total Receivables Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Receivables

Get a 7-Day Free Trial

9.68

5.82

4.33

4.71

2.58

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Total Receivables	Get a 7-Day Free Trial															5.47	-	2.58	4.10	-

PHAXIAM Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

PHAXIAM Therapeutics Total Receivables Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

PHXM:USA 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.